CCL2 and metabolic syndrome: Additionally, the underlying pathology of metabolic syndrome (MetS) involves insulin resistance, which activates the IKKβ/NF-κB signaling pathway, thereby promoting the expression of monocyte chemoattractant protein-1 (MCP-1).